Thermo Fisher Scientific Inc. (TMO) Holdings Reduced by Boston Common Asset Management LLC

Boston Common Asset Management LLC lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,361 shares of the medical research company’s stock after selling 207 shares during the quarter. Boston Common Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $2,015,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc lifted its position in shares of Thermo Fisher Scientific by 1.2% during the third quarter. Vanguard Group Inc now owns 29,271,095 shares of the medical research company’s stock worth $7,144,489,000 after purchasing an additional 347,836 shares in the last quarter. BlackRock Inc. lifted its position in shares of Thermo Fisher Scientific by 3.7% during the fourth quarter. BlackRock Inc. now owns 26,177,278 shares of the medical research company’s stock worth $5,858,214,000 after purchasing an additional 944,035 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in shares of Thermo Fisher Scientific by 44,296.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 19,565,960 shares of the medical research company’s stock worth $87,000 after purchasing an additional 19,521,889 shares in the last quarter. FMR LLC lifted its position in shares of Thermo Fisher Scientific by 33.4% during the fourth quarter. FMR LLC now owns 8,671,713 shares of the medical research company’s stock worth $1,940,642,000 after purchasing an additional 2,172,574 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Thermo Fisher Scientific by 9.4% during the fourth quarter. Geode Capital Management LLC now owns 4,897,714 shares of the medical research company’s stock worth $1,094,013,000 after purchasing an additional 422,625 shares in the last quarter. 88.39% of the stock is currently owned by institutional investors.

Several brokerages have recently issued reports on TMO. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 price target on the stock in a research report on Wednesday, May 15th. Argus increased their price target on shares of Thermo Fisher Scientific from $285.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Needham & Company LLC reissued a “strong-buy” rating and set a $312.00 price target (up previously from $271.00) on shares of Thermo Fisher Scientific in a research report on Monday, April 22nd. Bank of America reissued a “buy” rating and set a $300.00 price target (up previously from $285.00) on shares of Thermo Fisher Scientific in a research report on Tuesday, April 16th. Finally, Robert W. Baird increased their price target on shares of Thermo Fisher Scientific from $270.00 to $288.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 26th. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $293.77.

In related news, SVP Gregory J. Herrema sold 19,808 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $253.29, for a total value of $5,017,168.32. Following the sale, the senior vice president now owns 25,688 shares of the company’s stock, valued at $6,506,513.52. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 50,713 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $273.21, for a total transaction of $13,855,298.73. Following the completion of the sale, the chief executive officer now directly owns 302,193 shares in the company, valued at approximately $82,562,149.53. The disclosure for this sale can be found here. In the last ninety days, insiders sold 76,320 shares of company stock worth $20,405,269. 0.45% of the stock is owned by corporate insiders.

Shares of NYSE:TMO opened at $262.91 on Tuesday. The company has a market capitalization of $104.69 billion, a P/E ratio of 23.64, a PEG ratio of 1.72 and a beta of 1.11. Thermo Fisher Scientific Inc. has a fifty-two week low of $202.83 and a fifty-two week high of $282.98. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.16 and a current ratio of 1.69.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 24th. The medical research company reported $2.81 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.74 by $0.07. The firm had revenue of $6.13 billion for the quarter, compared to analysts’ expectations of $6.04 billion. Thermo Fisher Scientific had a net margin of 12.89% and a return on equity of 17.06%. The firm’s revenue was up 4.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.50 earnings per share. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 12.19 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.baseballdailydigest.com/news/2019/05/21/thermo-fisher-scientific-inc-tmo-holdings-reduced-by-boston-common-asset-management-llc.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Recommended Story: What is the Federal Reserve?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.